Vergelijking

Pasireotid vs. Teduglutid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

396091-73-9

197922-42-2

Molecuulmassa

1047.21 g/mol

3752.13 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Teduglutid

Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pasireotid	Teduglutid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Pasireotid

Volledige vermelding →

Teduglutid

Volledige vermelding →

Frequently asked questions

What is the difference between Pasireotid and Teduglutid?: Pasireotid is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Teduglutid?: The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Teduglutid in Germany and the United States?: Duitsland: Pasireotid — Op recept, Teduglutid — Op recept. Verenigde Staten: Pasireotid — Op recept, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Teduglutid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Pasireotid and Teduglutid?

Pasireotid is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Teduglutid?

The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Teduglutid in Germany and the United States?

Duitsland: Pasireotid — Op recept, Teduglutid — Op recept. Verenigde Staten: Pasireotid — Op recept, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.